While the small sample size limits definitive clinical conclusions, these findings suggest a potential benefit of administering T-DXd in earlier treatment settings for HER2-low breast cancer, reinforcing the need for further research in this evolving landscape. This evidence concerns the gene ERBB2 and breast carcinoma.